CECCON, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 2.528
EU - Europa 1.484
AS - Asia 715
SA - Sud America 39
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 4.781
Nazione #
US - Stati Uniti d'America 2.485
DE - Germania 315
SG - Singapore 310
IT - Italia 251
CN - Cina 219
RU - Federazione Russa 199
IE - Irlanda 191
SE - Svezia 180
UA - Ucraina 94
GB - Regno Unito 89
HK - Hong Kong 79
CA - Canada 43
AT - Austria 39
BR - Brasile 31
FR - Francia 30
FI - Finlandia 29
VN - Vietnam 27
IN - India 23
BE - Belgio 21
ID - Indonesia 17
TR - Turchia 16
DK - Danimarca 14
JP - Giappone 8
PL - Polonia 8
NL - Olanda 6
IR - Iran 5
BG - Bulgaria 4
LT - Lituania 4
AR - Argentina 3
ZA - Sudafrica 3
ES - Italia 2
EU - Europa 2
KG - Kirghizistan 2
KR - Corea 2
MA - Marocco 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PY - Paraguay 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
YE - Yemen 1
Totale 4.781
Città #
Ann Arbor 502
Frankfurt am Main 215
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 188
Singapore 176
Houston 146
Milan 140
Wilmington 136
Ashburn 117
Dearborn 107
Jacksonville 89
Seattle 87
Hong Kong 79
New York 78
Cambridge 74
Santa Clara 54
Princeton 53
Nanjing 47
Vienna 36
Altamura 24
Lawrence 23
Shanghai 23
Nanchang 21
Beijing 19
Brussels 19
Jakarta 17
Lachine 15
San Diego 15
Boardman 14
Fremont 13
Guangzhou 12
Göttingen 12
Helsinki 12
Moscow 12
Los Angeles 10
Norwalk 10
Falls Church 9
Hangzhou 9
Lissone 9
Toronto 9
Andover 8
Council Bluffs 8
Munich 8
Ottawa 8
Edmonton 7
Jiaxing 7
Lodz 7
London 7
Pune 7
Shenyang 7
Taizhou 7
Düsseldorf 6
Hebei 6
Kunming 6
Nuremberg 6
Romola 6
Hefei 5
Jinan 5
Kiev 5
Kocaeli 5
Monza 5
Taku 5
Tianjin 5
Bucha 4
Cagliari 4
Changsha 4
Dong Ket 4
Fürstenwalde 4
Motta Di Livenza 4
Newark 4
Ningbo 4
Zhengzhou 4
Bonndorf 3
Boston 3
Cinisello Balsamo 3
Haikou 3
Lauterbourg 3
Nürnberg 3
Portsmouth 3
Redmond 3
Rome 3
São Paulo 3
Trento 3
Acton 2
Bishkek 2
Bradford 2
Carate Brianza 2
Castiglione Delle Stiviere 2
Catania 2
Cesa 2
Changchun 2
Chicago 2
Chiswick 2
Daejeon 2
Delhi 2
Desio 2
Kilburn 2
Lanzhou 2
Totale 3.495
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 372
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 307
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 288
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 259
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 241
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 230
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 217
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 212
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 210
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 208
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 188
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 176
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 175
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 174
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 168
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 147
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 145
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 143
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 136
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 133
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 126
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 126
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 124
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 105
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 92
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 91
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 74
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 69
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 62
Totale 4.998
Categoria #
all - tutte 18.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.324


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202069 0 0 0 0 0 0 0 0 0 0 53 16
2020/2021642 34 37 60 82 54 76 50 59 40 59 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/2025857 67 114 57 54 100 42 75 31 134 181 2 0
Totale 4.998